title: [Smooth induction and stable maintenance of hypertensive state for clinical response in angiotensin II-induced hypertension chemotherapy].
abstract: In angiotensin II (A II)-induced hypertension chemotherapy (IHC), the role of the level of hypertension induced by A II and pattern of maintenance of the state was investigated in 5,840 IHC records of 264 patients. The pattern of IHC records of each patient was evaluated according to the range of the mean elevated blood pressure (MBPe) and induced hypertension point (IHTP). The MBPe of each record was calculated from 5-7 randomly selected values. The range of MBPe from each record was estimated, while discarding the max and min values. IHTP was classified into three categories as follows: 1:160 > MBPe > or = 140, 2: MBPe > 160 and 140 > MBPe > or = 130; and 3: 130 > MBPe. The most frequent category of all records was determined as the IHTP of each patient. One point was added to IHTP, when the fluctuation range of MBPe was more than 10 mmHg, and when the other categories were mixed more than 25% among all records. The MBPe of CR + PR group were significantly higher than in the other non-response group. IHTP was also better in responders. Many patients aged below 40 responded poorly to A II, and the level of MBPe was significantly lower than that of patients above 40. It may be essential to induce the hypertensive level and maintain a stable state during IHC for enhancement of clinical effects. Symptoms accompanied during IHC such as chest oppressive sense, dull head pain, and abdominal discomfort were observed in half the patients, although the IHC procedure almost never had to be discontinued.
authors.affiliation: Division of Cancer Control, Tohoku University.
authors.forename: H
authors.initials: H
authors.lastname: Sato
authors.forename: M
authors.initials: M
authors.lastname: Hoshi
authors.forename: M
authors.initials: M
authors.lastname: Urushiyama
authors.forename: K
authors.initials: K
authors.lastname: Sugiyama
authors.forename: K
authors.initials: K
authors.lastname: Ishizuka
authors.forename: K
authors.initials: K
authors.lastname: Sato
mesh_terms: D000328:Adult; D000804:Angiotensin II / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000503:physiopathology
chemical_list: D000970:Antineoplastic Agents; D000804:Angiotensin II